ArticlePerspectives in clinical research
Cost analysis and drug utilization pattern in diabetic patients attending outpatient at tertiary care teaching hospital in South Gujarat.
Article in Perspectives in clinical research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Diabetes is a global health concern, and effective glycemic control relies on the rational use of antidiabetic agents, which can be evaluated through drug utilization studies to ensure cost-effective pharmacotherapy. Aims: The aim of the study was to analyze the costs and drug utilization pattern in diabetic patients with the objectives of direct cost analysis of drugs, indirect cost analysis, and cost index. Measurement of WHO prescribing core indicators, patient care indicators, and facility indicators, prescribed daily dose (PDD)/defined daily dose (DDD) ratio. Settings and Design: Participants were recruited from the Non-communicable disease and medicine OPD, and the study design was cross-sectional, observational, according to STROBE guidelines. Subjects and Methods: The study began after institutional review board approval, with data collected from 250 participants following informed consent. A total of 1500 prescriptions were analyzed using appropriate parameters for cost analysis and WHO core drug use indicators. Drugs were categorized under anatomical, therapeutic, and chemical/DDD system, and the PDD/DDD ratio was calculated. Statistical Analysis Used: Descriptive statistics in Microsoft Excel 2021. Results: The study results found that the hospital covered most costs (481.1 INR per encounter), while participants bore 102.1 INR for anti-diabetic drugs and 234.35 INR in indirect costs monthly. An average of 2.68 antidiabetic drugs per prescription, with 95.60% prescribed by generic name and 33.46% involving injections. Metformin was the most prescribed drug (88.1%). A total of 12 drugs had a PDD/DDD ratio of 1. Conclusions: The study met WHO prescribing, patient care, and facility indicators, adherence to guidelines, and key drugs dispensed from the hospital pharmacy, reducing direct costs to the hospital pharmacy and participants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.